Information Provided By: 
Fly News Breaks for September 17, 2018
CRSP
Sep 17, 2018 | 12:19 EDT
Piper Jaffray analyst Edward Tenthoff reiterates an Overweight rating on Crispr Therapeutics with a $67 price target after the company announced a collaboration with ViaCyte. ViaCyte is developing the stem cell therapy for insulin deficiency, but is currently limited by host rejection, Tenthoff tells investors in a research note. He points out that Crispr will develop gene-edited immuno-evasive properties into the cells, a potentially curative therapy. The analyst believes the collaboration leverages Crispr's gene-editing in diabetes.
News For CRSP From the Last 2 Days
CRSP
Apr 23, 2024 | 08:08 EDT
Meeting to be held in San Francisco on April 24 hosted by Mizuho.
